Study on comparison of efficacy of entecavir and adefovir dipivoxil in treatment of hepatitis B cirrhosis

Objective: To compare the therapeutic effect between entecavir (ETV) and adefovir dipivoxil (ADV) in patients with hepatitis B cirrhosis. Methods: A total of 83 patients with hepatitis B cirrhosis were included in this study. The patients were assigned into the ETV group (n=42) and the ADV group (n=41). All patients received routine treatment. Patients in the ETV group were treated with entecavir, while those in the ADV group were treated with adefovir dipivoxil. The curative time was for one year. The observed indicators in terms of therapeutic effect were: HBV DNA negative conversion rate, HBeAg negative conversion rate, life quality, hepatic fibrosis and inflammatory factors were all compared between the ETV group and ADV group. Results: At the end of treatment, the total effective rate in the ETV group was remarkably higher (83.33% vs 63.41%), with a significant difference in contrast to the ADV group (P=0.039). Compared with the ADV group, the HBV DNA negative conversion rate (65.85% vs 88.10%) and HBeAg negative conversion rate (12.20% vs 30.95%) of the ETV group were significantly higher (all P<0.05). In contrast to the ADV group, the serum levels of PC III, IV-C, LN, HA and TNF-alpha at the end of treatment in the ETV group were significantly decreased, and the QLQ-C30 score and serum IL-10 level were significantly increased (P<0.001). Conclusion: Compared with adefovir dipivoxil, entecavir has obvious advantages with better therapeutic effects, higher HBV-DNA negative conversion rate and HBeAg negative conversion rate, better results in life quality, and fewer responses of hepatic fibrosis and inflammation.

Automated summary

In patients with hepatitis B cirrhosis, entecavir has shown to be more effective compared to adefovir dipivoxil, with higher rates of HBV-DNA negative conversion and HBeAg negative conversion. Additionally, entecavir led to better improvements in life quality, hepatic fibrosis, and inflammation compared to adefovir dipivoxil.